
CJC-1295 without drug-affinity complex, 10 mg lyophilized, assayed at 99.0% HPLC purity with mass-spectrometric confirmation.
CJC-1295 without DAC is a modified GHRH fragment used as an analytical reference in peptide-stability and receptor-affinity studies. Every PureLabs lot of CJC-1295 (no DAC) is produced under GMP-aligned synthesis controls, assayed by an independent partner laboratory using reverse-phase HPLC with mass-spectrometric confirmation, and released only above the stated purity threshold of 99.0%. The certificate of analysis is lot-specific, carries the chromatogram and MS trace for the exact vial you receive, and stays archived under reference SEQ-1040 for as long as the batch exists.
Common laboratory questions about sourcing, purity, storage and shipping of CJC-1295 (no DAC).
Current stock assays at 99.0% by reverse-phase HPLC, confirmed by mass spectrometry at an independent laboratory. Any lot testing below the threshold is rejected rather than sold.
Yes. A lot-specific certificate of analysis including the HPLC chromatogram and MS trace accompanies every CJC-1295 (no DAC) order and remains retrievable under batch reference SEQ-1040.
Sealed lyophilized CJC-1295 (no DAC) is stable at −20 °C for at least 24 months; once reconstituted, hold at 2–8 °C and use within about three weeks.
Orders confirmed before 15:00 UTC dispatch the same working day in insulated, tracked cold-chain packaging, subject to the import rules of the destination country.
No. PureLabs supplies this compound strictly as reference material for in-vitro and laboratory research. It is not a medicine and is not for human or veterinary consumption.